4 active not recruiting, 2 recruiting, 1 terminated. 7 Phase 3.
By phase and status
Follow Follicular Lymphoma (FL): new trials by email Literature Review of Follicular Lymphoma (FL) trials Research Report on Follicular Lymphoma (FL)
Trials (filtered) newest first · largest first
All 7 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
SCTB35 injection, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | 93 | 2026-06-09 | 2026-08-13 |
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Epcoritamab, Prednisone, Rituximab - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 1095 | 2024-02-05 | 2026-08-04 |
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Recruiting | 822 | 2023-12-12 | 2026-10-06 |
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
Odronextamab, Rituximab, Cyclophosphamide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 733 | 2023-11-14 | 2026-02-06 |
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 109 | 2023-10-02 | 2026-04-17 |
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Epcoritamab, Rituximab, Lenalidomide - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | 549 | 2022-09-20 | 2026-07-08 |
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Zandelisib, Rituximab, Bendamustine - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 3 | Terminated | 82 | 2021-08-13 | 2024-11-04 |
Narrower conditions
Lymphoma, Follicular (7) · Lymphoma, Non-Hodgkin (3) · Lymphoma (2) · Neoplasms (2) · Recurrence (2) · Lymphoma, B-Cell, Marginal Zone (1)
Broader conditions
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms by Histologic Type (7) · Lymphoma (5) · Neoplasms (5) · Lymphoma, Non-Hodgkin (4) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Lymphoma, B-Cell (1)
Interventions
Rituximab (7) · Cyclophosphamide (5) · Prednisone (5) · Doxorubicin (4) · Lenalidomide (4) · Vincristine (4) · Bendamustine Hydrochloride (3) · Methylprednisolone (2) · Prednisolone (2) · ME-401 (1) · R-CHOP protocol (1) · obinutuzumab (1) · tisagenlecleucel (1)
Sponsors
Genmab (2) · Regeneron Pharmaceuticals (2) · MEI Pharma, Inc. (1) · Novartis Pharmaceuticals (1) · Sinocelltech Ltd. (1)
Countries
Australia (6) · Poland (6) · Spain (6) · Taiwan (6) · Belgium (5) · Canada (5) · Czechia (5) · France (5) · Italy (5) · South Korea (5) · Turkey (Türkiye) (5) · United Kingdom (5) · United States (5) · Austria (4) · Brazil (4)
Results publications
PMID 41371238
NIH funding
2023 (3)